TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
Authors
Keywords
-
Journal
Acta Neuropathologica Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-11-03
DOI
10.1186/s40478-021-01270-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib
- (2020) Zhaohui Wang et al. MOLECULAR CANCER RESEARCH
- Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma
- (2019) Mwangala Precious Akamandisa et al. NEURO-ONCOLOGY
- The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update
- (2018) Enis Afgan et al. NUCLEIC ACIDS RESEARCH
- Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma
- (2018) Maria Tsoli et al. Oncotarget
- Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
- (2018) Anne Berberich et al. CLINICAL CANCER RESEARCH
- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- (2018) Lukasz Skalniak et al. Cancers
- Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
- (2017) Audrey Laroche-Clary et al. Journal of Hematology & Oncology
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
- (2017) Robin M Meyers et al. NATURE GENETICS
- Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
- (2017) Maryam Zanjirband et al. Oncotarget
- Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors
- (2017) Cheng Xu et al. Oncotarget
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
- (2016) Amy Bredlau et al. Current Neuropharmacology
- Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment
- (2016) Zhiping Zhou et al. Current Neuropharmacology
- Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
- (2016) Hamid Nikbakht et al. Nature Communications
- Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
- (2015) Catherine S Grasso et al. NATURE MEDICINE
- Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
- (2015) Lindi Chen et al. Oncotarget
- DIPG in Children – What Can We Learn from the Past?
- (2015) Magimairajan Issai Vanan et al. Frontiers in Oncology
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
- (2014) Gang Wu et al. NATURE GENETICS
- Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
- (2014) Pawel Buczkowicz et al. NATURE GENETICS
- Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
- (2014) Kathryn R Taylor et al. NATURE GENETICS
- Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
- (2014) Liwei Zhang et al. NATURE GENETICS
- H3F3A K27M Mutation in Pediatric CNS Tumors
- (2013) Gerrit H. Gielen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of Diffuse Pontine Gliomas in Children: Recent Developments
- (2013) Rejin Kebudi et al. PEDIATRIC DRUGS
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
- (2012) Dong-Anh Khuong-Quang et al. ACTA NEUROPATHOLOGICA
- Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
- (2012) Rintaro Hashizume et al. JOURNAL OF NEURO-ONCOLOGY
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
- (2012) Jeremy Schwartzentruber et al. NATURE
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
- (2012) Gang Wu et al. NATURE GENETICS
- Paediatric and adult malignant glioma: close relatives or distant cousins?
- (2012) Chris Jones et al. Nature Reviews Clinical Oncology
- Diffuse intrinsic pontine glioma: poised for progress
- (2012) Katherine E. Warren Frontiers in Oncology
- Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
- (2011) Hong Shen et al. CURRENT PHARMACEUTICAL DESIGN
- p53 post-translational modification: deregulated in tumorigenesis
- (2010) Chao Dai et al. TRENDS IN MOLECULAR MEDICINE
- Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study
- (2008) Kristin A. Bradley et al. NEURO-ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search